High prevalence of MUTYH associated polyposis among minority populations in Israel, due to rare founder pathogenic variants.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
07 2023
Historique:
received: 16 07 2022
revised: 07 01 2023
accepted: 09 01 2023
medline: 30 6 2023
pubmed: 6 2 2023
entrez: 5 2 2023
Statut: ppublish

Résumé

Autosomal recessive conditions are common in consanguineous populations. Since consanguinity is common in the Israeli Arab population, we evaluated the rate of MUTYH polyposis (MAP) among polyposis patients in this population and studied Pathogenic Variants (PVs) spectrum. We reviewed health records of all Arab and Druze polyposis patients referred for counseling during 2013-2020 who fulfilled the Israeli Genetic Society criteria for MUTYH/APC testing, in a tertiary center in Northern Israel and four additional gastro-genetic clinics in Israel. The Northern cohort included 37 patients from 30 unrelated families; 8(26.6%) carried bi-allelic MUTYH PVs. The major variant p.Glu452del was detected in 6/8 Druze and Muslim families who shared the same haplotype. Other PVs detected in both cohorts included p.Tyr56Ter, p.His57Arg, c.849+3A>C, p.Ala357fs, and p.Tyr151Cys. Among bi-allelic carriers, 88% reported consanguinity, and 100% had positive family history for polyposis or colorectal cancer (CRC). Generally, the age of CRC was 10 years younger than reported in the general MAP population. MAP accounted for 27% of polyposis cases in the Arab population of Northern Israel. PVs spectrum is unique, with high frequency of the founder variant p.Glu452del. Our results may inform the genetic testing strategy in the Israeli Arab population.

Sections du résumé

BACKGROUND
Autosomal recessive conditions are common in consanguineous populations. Since consanguinity is common in the Israeli Arab population, we evaluated the rate of MUTYH polyposis (MAP) among polyposis patients in this population and studied Pathogenic Variants (PVs) spectrum.
METHODS
We reviewed health records of all Arab and Druze polyposis patients referred for counseling during 2013-2020 who fulfilled the Israeli Genetic Society criteria for MUTYH/APC testing, in a tertiary center in Northern Israel and four additional gastro-genetic clinics in Israel.
RESULTS
The Northern cohort included 37 patients from 30 unrelated families; 8(26.6%) carried bi-allelic MUTYH PVs. The major variant p.Glu452del was detected in 6/8 Druze and Muslim families who shared the same haplotype. Other PVs detected in both cohorts included p.Tyr56Ter, p.His57Arg, c.849+3A>C, p.Ala357fs, and p.Tyr151Cys. Among bi-allelic carriers, 88% reported consanguinity, and 100% had positive family history for polyposis or colorectal cancer (CRC). Generally, the age of CRC was 10 years younger than reported in the general MAP population.
CONCLUSIONS
MAP accounted for 27% of polyposis cases in the Arab population of Northern Israel. PVs spectrum is unique, with high frequency of the founder variant p.Glu452del. Our results may inform the genetic testing strategy in the Israeli Arab population.

Identifiants

pubmed: 36740502
pii: S1590-8658(23)00162-7
doi: 10.1016/j.dld.2023.01.151
pii:
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

880-887

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Conflict of interest No conflict of interest declared by the authors.

Auteurs

Gili Reznick Levi (G)

The Genetics Institute, Rambam Health Care Campus, Haifa, Israel. Electronic address: g_reznick@rambam.health.gov.il.

Yael Goldberg (Y)

Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Hanna Segev (H)

The Genetics Institute, Rambam Health Care Campus, Haifa, Israel.

Itay Maza (I)

Gastroenterology Department, Rambam Medical Center, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Yuri Gorelik (Y)

Gastroenterology Department, Rambam Medical Center, Haifa, Israel.

Ido Laish (I)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gastroenterology Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Zohar Levi (Z)

Division of Gastroenterology, Rabin Medical Center, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Inbal Kedar (I)

Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel.

Sonia Naftali Nathan (S)

Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel.

Nitzan Sharon Swartzman (N)

Institute of Medical Genetics, Meir Medical Center, Kfar Saba, Israel.

Naim Abu Freha (N)

The Institute of Gastroenterology and Hepatology, Beer Sheva, Israel; Soroka University Medical Center, Faculty of Health Sciences, Beer Sheva, Israel.

Maya Paritsky (M)

Baruch Padeh Medical Center, Poriya, Israel; Faculty of Medicine, Bar Ilan University, Galilee, Israel.

Gad Rennert (G)

The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Clalit National Cancer Control Center and Personalized Medicine Program, Haifa, Israel; Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel.

Hagit Baris Feldman (H)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Genetics Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Tamar Paperna (T)

The Genetics Institute, Rambam Health Care Campus, Haifa, Israel.

Karin Weiss (K)

The Genetics Institute, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Elizabeth E Half (EE)

Gastroenterology Department, Rambam Medical Center, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH